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Loss of heterozygosity (LOH) of chromosomal regions bearing tumor suppressors is a key event in the evolution of
epithelial and mesenchymal tumors. Identification of these regions usually relies on genotyping tumor and
counterpart normal DNA and noting regions where heterozygous alleles in the normal DNA become homozygous in the
tumor. However, paired normal samples for tumors and cell lines are often not available. With the advent of
oligonucleotide arrays that simultaneously assay thousands of single-nucleotide polymorphism (SNP) markers,
genotyping can now be done at high enough resolution to allow identification of LOH events by the absence of
heterozygous loci, without comparison to normal controls. Here we describe a hidden Markov model-based method to
identify LOH from unpaired tumor samples, taking into account SNP intermarker distances, SNP-specific
heterozygosity rates, and the haplotype structure of the human genome. When we applied the method to data
genotyped on 100 K arrays, we correctly identified 99% of SNP markers as either retention or loss. We also correctly
identified 81% of the regions of LOH, including 98% of regions greater than 3 megabases. By integrating copy number
analysis into the method, we were able to distinguish LOH from allelic imbalance. Application of this method to data
from a set of prostate samples without paired normals identified known regions of prevalent LOH. We have developed
a method for analyzing high-density oligonucleotide SNP array data to accurately identify of regions of LOH and
retention in tumors without the need for paired normal samples.
Citation: Beroukhim R, Lin M, Park Y, Hao K, Zhao X, et al. (2006) Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS
Comput Biol 2(5): e41. DOI: 10.1371/journal.pcbi.0020041
Introduction
Loss of heterozygosity (LOH) refers to change from a state
of heterozygosity in a normal genome to a homozygous state
in a paired tumor genome. LOH is most often regarded as a
mechanism for disabling tumor suppressor genes (TSGs)
during the course of oncogenesis [1,2]. Although LOH is often
thought to result from copy-loss events such as hemizygous
deletions, a large proportion of LOH results from copy-
neutral events such as chromosomal duplications [3,4].
Analyzing LOH data across multiple tumor samples can
point to loci harboring TSGs or identify subtypes of tumors
with different somatic genetic proﬁles [5,6].
Single nucleotide polymorphisms (SNPs) are the most
common genetic variation in the human genome and can
be used to search for germline genetic contributions to
disease. To that end, oligonucleotide SNP arrays have been
developed to simultaneously genotype thousands of SNP
markers across the human genome [7–9]. The density,
distribution, and allele speciﬁcity of SNPs makes them
attractive for high-resolution analyses of LOH and copy
number alterations in cancer genomes [3,6,10–15].
Traditionally, LOH analyses require the comparison of the
genotypes of the tumor and its normal germline counterpart.
However, for cell line, xenograft, leukemia, and archival
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generations of SNP arrays provide high enough marker
density to make it feasible to identify regions of LOH by the
absence of heterozygous loci (which we call inferred LOH),
rather than by comparison to the paired normal. For
example, the homozygosity mapping of deletions method
was developed to use highly polymorphic microsatellite
markers to identify regions of hemizygous deletion in
unpaired tumor cell lines [16], and a simple method of
inferring LOH using the product of the probability of
homozygosity in neighboring SNPs was able to identify 80%
of LOH in 10 K SNP array data from one sample [3,17]. SNP
markers are less polymorphic than microsatellite markers,
however, and the haplotype structure may render closely
located SNPs dependent in their genotype calls. We hypothe-
sized that a method that infers LOH with high accuracy would
have to account for not only the varied heterozygosity rates of
SNP markers, but also their varied intermarker distances, as
well as genotyping errors and the interdependence of SNP
alleles based on the haplotype structure of the genome.
We approached this problem by developing a hidden
Markov model (HMM) to infer LOH. HMMs are appropriate
for inferring the unobserved underlying states that give rise
to an observed chain of data, using multiple sources of
information. They have been used to model biological data in
diverse applications such as sequence analysis [18–20], linkage
studies [21,22], and array-comparative genomic hybridization
[15,23]. SNP genotypes along a chromosome are chain-like
and thus suitable for HMM analysis. The model we developed
incorporates SNP intermarker distances, SNP-speciﬁc heter-
ozygosity rates, and genotyping error rate. We investigated its
ability to accurately identify regions of LOH in unpaired
tumors, both at low genotyping densities (10,000 markers
across the genome), where neighboring SNPs could be
considered independent, and at high densities (over 100,000
markers across the genome), where linkage disequilibrium
leads to dependencies between neighboring SNPs. We further
applied this method to data from prostate cell lines,
xenografts, and metastases lacking paired normals, to test
its ability to identify known regions of prevalent LOH
containing known and putative TSGs.
Results
A Basic HMM for Inferring LOH from Unpaired Tumor
Samples
The components of a HMM are the unobserved states, the
observed measurements, the emission probabilities connect-
ing these two, the transition probabilities between the
unobserved states, and the initial probabilities of the states
at the beginning of the chain (Figure 1). To infer LOH in
unpaired tumor samples, we implemented a HMM with two
unobserved states: loss (LOSS) and retention (RET) and the
observed genotypes, reduced to homozygous (Hom; AA or
BB), heterozygous (Het; AB), and ‘‘No Call.’’ We conceptual-
ized that the observed genotypes are generated by the
unobserved LOH states according to the emission probabil-
ities of the HMM.
Emission probabilities. For a SNP under the RET state, we
observed Het calls with a probability equal to the hetero-
zygosity rate of each SNP, which we estimated from normal
samples (see Materials and Methods). For a SNP under the
LOSS state, we always observed a Hom call unless a
genotyping or SNP mapping error has occurred. Since
genotyping errors occur at a rate , 0.01 [7], we set the
emission probability of a Het call under the LOSS state to
0.01. The emission probability of the Hom call at a SNP is one
minus the emission probability of the Het call at the SNP. A
SNP with ‘‘No Call’’ could have had either an unobserved
Hom or Het call, and is therefore emitted with a probability
of 1 regardless of its underlying LOH state. As a result, a ‘‘No
Call’’ does not bias the inference toward either LOSS or RET.
Initial probabilities. These probabilities, denoted by
P0(RET) and P0(LOSS) ¼ 1  P0(LOSS), specify the probabil-
ities of RET and LOSS for the p-terminal marker on a
chromosome. They also specify the probabilities of the RET
and LOSS states for any marker, if no other information
exists for that marker. Assuming Het markers are observed in
regions of LOSS only as a result of genotyping or mapping
errors, the observed proportion of Het markers in a tumor
sample is P0(RET)3average heterozygosity rateþP0(LOSS)3
SNP error rate. As the SNP error rate is small the second term
can be omitted. Therefore we estimated P0(RET) by dividing
the proportion of Het markers by the average heterozygosity
rate of SNPs in the population.
Transition probabilities. These probabilities describe the
dependence between the LOH states of adjacent markers. For
Figure 1. The Elements Included in the HMM for LOH Inference
Unobserved LOH states (LOSS or RET) of SNP markers generate observed
genotype calls via emission probabilities. The solid arrows indicate the
transition probabilities between LOH states, and the dashed arrows
indicate LD-induced dependencies between consecutive SNP genotypes.
DOI: 10.1371/journal.pcbi.0020041.g001
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Synopsis
A key event in the generation of many cancers is loss of
heterozygosity (LOH) of chromosomal regions containing tumor
suppressor genes, whereby one parent’s version of the tumor
suppressor is lost. As we develop a better understanding of the
molecular mechanisms that generate different cancers, a description
of the LOH events underlying these cancers is forming an important
part of their classification. Generally, detection of LOH relies on
comparison of the tumor’s genome to the normal genome of the
individual. Unfortunately, for many tumors, including most exper-
imental models of cancer, the normal genome is not available.
Therefore, the authors have developed a hidden Markov model-
based method that evaluates the probability of LOH at all sites
throughout the genome, based on high-resolution genotyping of
only the tumor. They were able to achieve high levels of accuracy,
specifically by taking into account the haplotype block structure of
the genome. Application of this method to a set of 34 prostate
cancer samples allowed the authors to identify the locations of the
known and suspected tumor suppressor genes that are targeted by
LOH.
Tumor-Only LOH Inference of SNP Dataany two adjacent SNP markers, we ﬁrst deﬁned h as the
probability that the state of the ﬁrst marker does not inform
the state of the second (i.e., that the LOH state of the second
marker is distributed according to the initial LOH state
probabilities). Empirically, nearby markers tend to have the
same LOSS or RET state, while distant markers do not. To
capture this observation we calculate h using an increasing
function h ¼ (1 e
 2d), where d is the physical distance (in the
unit of 100 megabases [Mb] ’ 1 morgan) between the two
adjacent SNP markers. With probability 1   h, the two
markers have the same LOH state. Therefore, the marker-
speciﬁc transition probabilities of the second marker being
LOSS given the LOH state of the ﬁrst marker are:
PðLOSSjLOSSÞ¼h   P0ðLOSSÞþð 1   hÞ
and PðLOSSjLOSSÞ¼h   P0ðLOSSÞþð 1   hÞ:
ð1Þ
The probability of RET at the second marker is one minus
these two probabilities. This transition probability model is
the same as those used in the ‘‘instability-selection’’ model for
LOH analysis [24,25], and is reminiscent of Haldane’s map
function in linkage analysis [22]. We used a ﬁxed scaling of d,
instead of estimating it as in the instability-selection model,
but this does not affect the method performance (see below).
In addition, the empirical transition frequencies estimated
from observed LOH calls in paired normal and tumor
samples agreed well with the transition probabilities esti-
mated by this model (Figure 2).
Inferring LOH states. The HMM and these emission, initial,
and transition probabilities specify the joint probability of
the observed SNP genotypes and the unobserved LOH states
in one chromosome of a sample. We applied the forward-
backward algorithm [20] separately to each chromosome of
each sample to obtain the LOSS probability for each SNP
given all the genotype data on the chromosome. Alterna-
tively, the Viterbi algorithm can be used; we found this gave
similar LOH calls in 98.8% of SNPs (unpublished data). LOSS
and RET calls were made using the least stringent threshold:
LOSS if the SNP has a probability of LOSS greater than 0.5
and RET otherwise.
An alternative inference method for HMM is the Baum-
Welch algorithm [20], which estimates the model parameters
together with unobserved LOH states by an iterative
procedure. We chose not to use this algorithm, as there are
many parameters in the model (e.g., the transition proba-
bilities depend both on the LOH states and on the distance
between adjacent markers), but relatively few data points at
each SNP position to estimate these parameters. This could
lead the Baum-Welch algorithm to converge to local maxima
when estimating optimal model parameters. Instead, we set
biologically reasonable model parameters as above, with
smooth transition probabilities that agreed with the observed
data (Figure 2). In addition, we showed that the model
inference accuracy is robust to the speciﬁed parameters in
the initial, emission, and transition probabilities (see below).
The performance of the basic HMM. We compared tumor-
only inferred LOH to the observed LOH calls determined by
paired analysis of tumor and normal genotypes, using 10 K
SNP array data from autosomes of 14 lung and breast cancers
and EBV-transformed normal cell line pairs (Figure 3A) [15].
Here, 17,511 of 17,922 markers observed as LOSS in tumor/
normal pairs were called LOSS in unpaired tumors by the
HMM (for a sensitivity of 97.7%), and 15,962 of 16,364
markers that were observed as RET in tumor/normal pairs
were called RET in unpaired tumors (for a speciﬁcity of
97.5%) (Table S1A).
This initial analysis does not, however, account for the
SNPs that are homozygous in both tumor and the paired
normal, and thus are noninformative. A string of such
homozygous SNPs may be falsely called LOSS in the HMM
analyses of unpaired tumors, but not accounted for in the
above comparison of observed and inferred LOH states (the
red arrows in Figure 3A point to two examples). To estimate
the extent of such potentially falsely inferred LOH, we
assigned an LOH state (LOSS or RET) to those noninforma-
tive markers for which the ﬁrst informative marker on either
side had the same LOH state. For example, a noninformative
marker would be assigned a LOSS state if the nearest ﬂanking
informative markers were both in the LOSS state. In this
analysis, the noninformative makers assigned a RET state
were falsely inferred as LOSS at a rate of 6.8% (10 K array)
(Table S1A). Not surprisingly, false inferences of RET were
rare, occurring at a rate of 0.3%. Taking into account the
noninformative markers in this way, the overall sensitivity
remained high at 99.1%, but the speciﬁcity dropped to
94.3%. As an alternative approach to the use of ﬂanking
markers, we also inferred the LOH states of uninformative
markers through the application of an HMM to the paired
tumor/normal data, with nearly identical results (Protocol S1
and Table S2).
Linkage Disequilibrium Attenuates the Performance of the
Basic HMM at High SNP Density
With these methods in place, we next applied the basic
HMM to 100 K SNP array data from two prostate cancers and
Figure 2. Comparison of Predicted to Empirically Determined LOH
Transition Probabilities
Empirically determined transition probabilities (circles) between RET loci
(top graph) and LOSS loci (bottom graph) are compared to those
predicted by Equation 1 (black lines).
DOI: 10.1371/journal.pcbi.0020041.g002
PLoS Computational Biology | www.ploscompbiol.org May 2006 | Volume 2 | Issue 5 | e41 0325
Tumor-Only LOH Inference of SNP Datatwo lung cancer cell lines along with paired normal DNA,
which were not included in the 10 K dataset. Here, the
number of noninformative regions inferred as LOSS in-
creased signiﬁcantly (Figure 3B). When noninformative
marker status was assigned as above, many of these regions
were deemed false regions of LOSS, and the speciﬁcity of the
HMM decreased to 92.2% (Table S1B). Furthermore, when
100 K SNP array data derived from normal samples alone
were analyzed, the basic HMM identiﬁed multiple regions of
LOH that by deﬁnition are false (Figure 4A). We found that
this occurred because, at high SNP densities regions of
linkage disequilibrium (LD) are probed multiple times,
resulting in strings of homozygous SNPs. Speciﬁcally, if both
parental chromosomes share the same haplotype, an ex-
tended stretch of homozygous genotypes will result. There-
fore the assumption, inherent in the basic HMM, of
independence between allele calls of adjacent or nearby
SNPs becomes erroneous, leading to false inferences of LOH.
An example is shown in Figure 4B, where the examination of
an area of false LOH reveals the presence of a region of LD
(dashed red box; also identiﬁed in the HapMap Project,
available at: http://www.hapmap.org).
HMM and Haplotype Correction that Incorporate LD
Information
As indicated above, within a region of LD, the observed
genotype of any marker depends not only on the underlying
LOH state, but also on the genotypes of the adjacent markers
(i.e., the two markers are dependent in genotype, indicated by
the broken arrows in Figure 1). Here we account for many of
these LD-induced SNP dependencies using an extension of
the basic HMM (referred to herein as the linkage disequili-
brium HMM or LD-HMM).
Expanded states and emission probabilities. We use the
same observed Het and Hom genotypes of the tumor sample
as in the basic HMM, but expand the unobserved LOH states
for a SNP marker from the previous two states (LOSS or RET)
to four states: Hom LOSS, Het LOSS, Hom RET, and Het
RET. Here Hom and Het represent the SNP marker’s
genotype in the unobserved normal sample. For example,
‘‘Hom LOSS’’ indicates that the SNP is homozygous in normal
and LOH in tumor. The state ‘‘Hom LOSS’’, ‘‘Het LOSS’’, and
‘‘Hom RET’’ will result in homozygous genotype calls in the
tumor unless genotyping or mapping error occurs, so the
emission probability of the Hom genotype from these three
states is set to (1 – SNP error rate). The state ‘‘Het RET’’ will
result in a heterozygous SNP call in the tumor unless a
genotyping or mapping error happens, so the emission
probability of the Hom genotype from this state is set to
the SNP error rate. The emission probability of the Het
genotype is 1 minus that of the Hom genotype.
Transition probabilities. The transition probabilities now
reﬂect both the probability of a state change from RET to
LOSS (LOH state), and a state change from Het to Hom
(genotype state). We estimated genotype dependencies as
the probability, for each SNP marker, of the next adjacent
SNP marker toward q-arm being Hom (or Het), given the
current SNP marker being Hom (or Het), in a reference set
of normal samples (see Materials and Methods). We
denoted these conditional probabilities for SNP i by
P(Uiþ1 ¼ HomjUi ¼ Hom) and P(Uiþ1 ¼ HetjUi ¼ Het).
P(Uiþ1 ¼ HetjUi ¼ Hom) and P(Uiþ1 ¼ HomjUi ¼ Het) are
one minus the previous two probabilities, respectively.
When there were not enough data to estimate these
probabilities at a marker, the SNP-speciﬁc heterozygosity
rate was estimated from the reference set and used
as the unconditional probabilities—e.g., replacing
P(Uiþ1 ¼ HetjUi ¼ Hom) by P(Uiþ1 ¼ Het), the heterozygosity
rate of marker i þ 1. Next, we built the transition
probabilities by combining the above genotype dependence
probabilities with the probability of an LOH state change.
Figure 3. Comparison of LOH Inferred from Unpaired Tumors to LOH
Observed in Tumor/Normal Pairs
(A) Results from 10 K SNP array data. Each column represents a sample,
with SNP markers from Chromosome 10 displayed from the p terminus
(top) to the q terminus (bottom) (not all markers are displayed at this
resolution). Tumor/normal observations (left) represent direct compar-
isons of tumor to normal genotypes. Here, SNP markers observed as
having undergone LOH are indicated in blue, retention is shown in
yellow, and noninformative SNPs are indicated in grey. Inferences from
unpaired tumor data represent the probability of each SNP having
undergone LOH, as made by the basic HMM (center) and HC/LD-HMM
(right). Here, a high probability of LOH (LOSS) is also indicated in blue, a
high probability of retention (RET) is indicated in yellow, and
indeterminate SNPs with an almost equal probability of either state are
indicated in white. Occasionally, regions that are noninformative in the
tumor/normal comparison are falsely inferred as LOH by the basic HMM
in the unpaired data (red arrows); some of these false regions are
corrected by the HC/LD-HMM (green arrows).
(B) Results from 100 K SNP array data, shown as in (A). Data from
Chromosome 21 are shown to highlight the detection of false LOH in the
analysis of unpaired tumor data, and are not representative of the
frequency of true LOH events in this sample set. Almost all regions falsely
inferred as LOH by the basic HMM are correctly inferred by the HC/LD-
HMM. The blue arrows indicate a region of true LOH, which is correctly
identified by both the basic and HC/LD-HMM.
DOI: 10.1371/journal.pcbi.0020041.g003
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Tumor-Only LOH Inference of SNP DataWe denote the underlying LOH state of marker i by UiVi,
where Ui is either Hom or Het and Vi is either LOSS or
RET. Suppose the current SNP i is in the ‘‘Hom LOSS’’ state
while the next SNP i þ 1 is in the ‘‘Het RET’’ state. For this
to happen, two independent events must occur: a homo-
zygous genotype is followed by a heterozygous genotype in
the normal with the probability P(Uiþ1 ¼ HetjUi ¼ Hom)
estimated as above, and the LOH state changes from LOSS
to RET in the tumor with the probability
P(Viþ1 ¼ RETjVi ¼ LOSS) as speciﬁed in the transition
probability of the basic HMM. The transition probability
from ‘‘Hom LOSS’’ to ‘‘Het RET’’ is then the product of
these two probabilities. In general, the transition probability
of going from LOH state UiVi to Uiþ1Viþ1 is
P(Uiþ1Viþ1jUiVi) ¼ P(Uiþ1jUi)P(Viþ1jVi).
Inferring LOH states. With the addition of the initial
probabilities (which are the same as the basic HMM), the
HMM parameters were fully speciﬁed and the forward-
backward algorithm was used to obtain the probability of
the LOH state being LOSS (either ‘‘Hom LOSS’’ or ‘‘Het
LOSS’’) for every SNP, given all the observed SNP calls along
one chromosome of a tumor sample. Application of the LD-
HMM to the 100 K dataset of normals, in place of the basic
HMM, reduced the frequency of loss calls from 4.7% to 1.5%
of markers (Figure 4C). Likewise, application of the LD-HMM
to the 100 K training dataset improved the speciﬁcity of
LOSS calls from 92.2% to 97.4%, while decreasing the
sensitivity only from 99.8% to 99.6% (Table S1).
Empirical haplotype correction. We posited that the
remaining regions of falsely inferred LOH resulted from
three speciﬁc deﬁciencies of the LD-HMM. First, regions of
LD might be present in a relatively small subset of patients
[26]. Across the population as a whole, the genotypes of the
neighboring SNPs within these LD regions correlate only
weakly, and thus are not taken into account by the LD-HMM.
Second, LD may happen between markers that are not
immediately adjacent. Finally, in the LD-HMM, the depend-
ency information among SNPs are estimated for the reduced
genotype calls (Hom/Het) rather than from real genotypes. To
try to address these concerns we also developed an empirical
haplotype correction method, in which we applied a
computational correction to the inferred LOH regions from
either the basic or LD-HMMs (herein referred to as HC-HMM
and HC/LD-HMM, for the haplotype-corrected versions of
the basic and LD-HMMs). For every putative LOH region
called by HMM (LOH probability . 0.5 for all the SNP
markers in the region but   0.5 for the SNPs at the
boundaries of the region; containing mostly Hom SNP
Figure 4. Accounting for LD by the LD-HMM Significantly Reduces False LOH Inferences from Data Obtained at High Marker Density
(A) Inferences from the basic HMM applied to 100 K SNP array data are shown for Chromosome 4 in normal samples. Data are shown as in Figure 3.
(B) The genotypes of one region of falsely inferred LOH reveal a region of linkage disequilibrium (dashed red box), also identified by the HapMap
project. The sample in column ‘‘D’’ contains one haplotype, the samples in columns ‘‘E’’ through ‘‘K’’ contain another haplotype, and the samples in
columns ‘‘A’’ through ‘‘C’’ are heterozygous.
(C) Improved LOH inferences after application of the LD-HMM.
DOI: 10.1371/journal.pcbi.0020041.g004
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Tumor-Only LOH Inference of SNP Datagenotypes), we determine whether over 95% of the homo-
z y g o u sm a r k e r si nt h i sr e g i o ni na nu n r e l a t e dn o r m a l
reference sample are genotypically identical to the LOH
region of the tumor sample. If this is the case, then the tumor
sample is likely to share its haplotype structure with the
reference sample in this region. Thus, homozygosity is likely
due to LD rather than LOH, and the region is removed by
setting the LOH probability of all the SNPs in the region to
the LOH probability of the SNP marker just outside the
bottom boundary of the region. This haplotype correction
further improved speciﬁcity over the LD-HMM, in both the
training 10 K and 100 K datasets, without signiﬁcant loss of
sensitivity (Figure 3 and Table S1A and S1B).
The HC/LD-HMM Infers LOH with High Accuracy in a 100 K
Validation Dataset
To validate these results, we extended the analysis to a set
of 100 K data obtained from two lung cancer cell lines and six
gliomas with paired normals, that had not been used in any of
our prior analyses. Here, the sensitivity and speciﬁcity of the
HC/LD-HMM were 98.7% and 99.3%, respectively (Tables 1
and S1C). Compared to the basic HMM, the HC/LD-HMM led
to a greater than 8-fold reduction of potentially false LOH
inferred at noninformative markers in the 100 K data, but
remained highly sensitive for real LOH events. Interestingly,
once the haplotype block structure of the human genome is
taken into account, the performance of HMM-based inferred
LOH is better for 100 K data than 10 K data, presumably due
to the denser SNP coverage of the 100 K array.
Effect of Ethnicity
Given the importance of taking into account haplotype
block structure, which is known to vary between ethnic groups
[26], we sought to delineate the effect of mismatching the
ethnicities of tumor and reference samples. To that end, we
replaced the 60 Caucasian reference samples (the CEPH set)
with, in turn, 89 East Asian samples (the JHC set), and 60
African samples (the YOR set) [27]. With each set, we then
retested the basic HMM against our training set of tumor
samples (Table S3). In each case, the sensitivity of the method
remained almost unchanged, but the speciﬁcity dropped
somewhat: from 97.4% in the case of the appropriately
matched CEPH samples, to 97.0% and 93.8% in the cases of
the JHC and YOR samples, respectively. The LD-HMM relies
on estimates of genotyping dependencies between neighbor-
ing SNPs, which in turn are determined by the size of regions
of LD in the reference datasets. Therefore, the similarity
between results using the CEPH and JHC samples may reﬂect
the similar size of regions of LD in the two groups, whereas the
poorer speciﬁcities using the YOR samples as a reference may
be due to the much smaller regions of LD in that group [27].
Conversely, the haplotype correction method relies on the
ability to match speciﬁc haplotypes present in the tumors to
those same haplotypes in the reference set. One might expect,
therefore, that use of the JHC samples as the reference set for
haplotype correction would result in poorer speciﬁcity than
use of a Caucasian reference set. That is in fact the case, with
the speciﬁcity of the HC/LD-HMM rising to only 98.3% when
JHC samples were used for the haplotype correction, rather
than the 99.0% when Caucasian samples were used (Table S3).
LOH Inference Is Robust to Model Parameter
Specifications
The methods described above rely on the empirical
estimates of a number of the parameters used in the initial,
emission, and transition probabilities of the HMM. To assess
whether the tumor-only inference methods were unduly
inﬂuenced by these estimates, we tested the performance of
the basic and LD-HMMs as we varied these parameters.
Speciﬁcally, the accuracy of the model results, as judged
against observed LOH in the paired tumor/normal data,
changed by less than 0.3% as the SNP error rate was varied
from 0.1% to 1% (10 K array). Moreover, when the SNP-
speciﬁc heterozygosity rates were replaced by an average
heterozygosity rate that was varied from 0.1 to 0.5 (10 K array)
or from 0.1 to 0.27 (100 K array), the accuracy of the model
results changed by less than 5% and 0.5%, respectively.
Likewise, use of 60 versus 89 reference samples (from the JHC
reference set) affected model accuracy by less than 0.1%. We
also found that varying the scaling factor d from 50 Mb to 200
Mb changed the LOH inferences of only 2% of SNP markers.
These results suggest that the basic and LD-HMMs should be
able to provide accurate LOH inferences in datasets that have
different error rates, heterozygosity rates, or LOH-retention
transition frequencies from the sample sets presented here,
and that the set of reference samples used for determination
of allele frequencies and dependencies need not be larger
than 60 individuals.
Why an HMM?
If the HMM is robust to parameter speciﬁcations, the
question naturally arises, Why institute an HMM-based
approach that requires these parameters, rather than a more
simplistic approach? The most obvious simple approach is to
calculate, for all n and in the reference set of normal samples,
the probability with which a window of n homozygous SNPs
occurs. Using this, one could determine a threshold number t:
Table 1. Sensitivity and Specificity of the Basic HMM and HC/LD-HMM
Basic HMM HC/LD-HMM
LOSS RET LOSS RET
Tumor/normal pairs LOSS (171,407) 170,190 (99.3%) 1,217 (0.7%) 169,129 (98.7%) 2,278 (1.3%)
RET (702,157) 42,417 (6.0%) 659,740 (94.0%) 4,791 (0.7%) 697,366 (99.3%)
The number and proportion of SNP markers in the 100 K validation dataset with LOSS or RET in tumor/normal pairs, inferred as LOSS or RET by the basic HMM and HC/LD-HMM applied to
the unpaired tumors. LOH states were assigned to noninformative markers to agree with the nearest flanking informative markers.
DOI: 10.1371/journal.pcbi.0020041.t001
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SNPs, that region is likely to be suffering LOH.
We applied such an approach (called NumHom) to our
training set of 100 K data, and found that it does not match
the speciﬁcity of the HC/LD-HMM for thresholds at which
reasonable sensitivities are reached (Table S4). Inspection of
the data (Figure S1) reveals that, as with the basic HMM
described above, much of this lack of speciﬁcity occurs due to
unexpectedly long stretches of homozygous SNPs in partic-
ular regions, due to linkage disequilibrium. Therefore, we
applied the haplotype correction method (described above)
to the output of the NumHom method, to remove those
regions of putative LOH that matched the genotypes of
equivalent regions in our reference normal dataset. As
expected, speciﬁcities increased markedly (Table S4), but at
the cost of unacceptable decreases in sensitivity. Again,
inspection of the data (Figure S1) revealed the reason: large
regions of LOH were divided into subregions by the
NumHom method, due to occasional intervening hetero-
zygous SNPs. Those subregions often match genotypically
their counterparts in the reference dataset, and are in-
correctly removed. Conversely, the HC/LD-HMM allows for
occasional heterozygous SNPs (representing genotyping
errors, possibly exacerbated in some tumor samples by small
amounts of contamination with normal cells) within large
regions of LOH. As these large regions of LOH are not split
into subregions by the HC/LD-HMM (Figure S1), the
haplotype correction is applied to the overarching large
region of LOH, which is retained.
The value of this HMM-based approach appears to be that
it can straightforwardly integrate multiple sources of in-
formation, including SNP-speciﬁc heterozygosity rates, hap-
lotype block structure, and genotyping error rates, to
generate a local probability of LOH. It appears that each of
these sources of information is necessary to obtain the
highest sensitivity and speciﬁcity. Undoubtedly, other ap-
proaches may be devised to integrate these sources of
information, but such approaches are likely to have a similar
complexity to the HMM-based methods.
Resolution of the HC/LD-HMM
The above analyses suggest that the HMM-based methods
are robust for inferring LOH on a per marker basis. We next
asked whether the HC/LD-HMM was equally effective in
detecting regions of LOH and whether detection of such
regions was inﬂuenced by their size. To this end, we
compared the ability of the tumor-only LOH analysis to
identify LOH regions observed from comparing paired
normal and tumor samples (Table 2). Here, we deﬁne a
LOH region in the paired analysis as containing at least three
LOH markers with any number of intervening noninforma-
tive markers, and with boundaries deﬁned in each direction
by two consecutive retention markers. We considered such a
region to have been ‘‘identiﬁed’’ by the tumor-only method, if
that method inferred a probability of LOH higher than 0.5
for more than 90% of the SNP markers in the region. In the
100 K datasets (both training and validation), the majority of
regions of LOH observed in paired tumor/normal analysis are
over 3 Mb or are covered by at least 100 SNP markers, and
more than 95% of these regions were identiﬁed using the
unpaired analysis. Not surprisingly, smaller regions of LOH
were detected less frequently. Overall, 80.8% of the regions of
LOH identiﬁed in tumor/normal pairs were also identiﬁed in
unmatched tumors in the 100 K SNP data (Table 2). A similar
analysis of the 10 K data suggests higher sensitivity for smaller
regions, apparently due to fewer such regions being identiﬁed
by the tumor/normal paired analysis (Table S5).
Integrating with Copy Number Analysis to Distinguish
Allelic Imbalance
As mentioned in the introduction, LOH arises due to
complete loss of one allele through hemizygous deletion
(copy loss) or through gene duplication (copy neutral). On the
other hand, heterozygous loci can erroneously be assigned a
homozygous genotype in settings of allele speciﬁc ampliﬁca-
tion (allelic imbalance). This will occur whether or not LOH is
determined using paired normals, and may present para-
doxical results, with recurrently ampliﬁed oncogenes seen as
potential TSGs. To address this issue we determined the copy
number at each SNP locus using the probe level signal
intensity data [15] and correlated the results with the LOH
analysis. We found that among the observed LOH from
normal/tumor pairs or the inferred LOH from unpaired
tumors (using the basic HMM), about 70% of SNPs have copy
number 2 (copy neutral LOH), 20% have copy number 1
(copy loss LOH), and 10% have copy number 3 or above
(ampliﬁcation with possible allelic imbalance) (Figure 5). In
contrast, among SNPs with observed retention from normal/
tumor pairs or inferred retention from unpaired tumors, a
lower percentage of markers have copy loss, and a higher
percentage have ampliﬁcations (Figure 5). The combined
LOH and copy number analysis can thus distinguish true
LOH from those caused by ampliﬁcation or allelic imbalance,
which can be excluded from downstream LOH analysis. In
addition, the copy number analysis can be used to distinguish
LOH events caused by copy neutral gene conversion and copy
number loss (Figure 5) [10,15]. In short, the vast majority of
the regions of LOH detected using SNP arrays either by
paired or unpaired analysis arises from copy neutral or copy
loss events. Interestingly, the high frequency of copy-neutral
LOH observed in these samples and others [3] suggests that
LOH and copy number analyses provide independent sets of
information pointing to TSGs.
Table 2. Sensitivity of the HC/LD-HMM by Size of LOH Region
Size of
Region
Number
of Regions
(Percent of
Total)
Number of
Informative
SNPs
(Mean 6 SD)
Proportion
Identified
by Tumor
Only
By Mb  1 54 (20.4%) 5.5 6 4.4 40.7%
1–3 43 (16.2%) 10.2 6 7.3 65.1%
3–10 46 (17.4%) 31 6 23 91.3%
.10 122 (46.0%) 437 6 412 100%
By number of SNPs 1–40 48 (18.1%) 4.6 6 2.6 25.0%
40–100 42 (15.8%) 9.3 6 5.6 71.4%
100þ 175 (66.0%) 314 6 392 98.3%
All regions 265 (100%) 210 6 350 80.8%
The percentage of LOH regions identified in analysis of 100 K data from tumor/normal
pairs that were also identified by the HC/LD-HMM applied to unpaired tumors, by size of
region and the number of SNPs probed.
SD, standard deviation.
DOI: 10.1371/journal.pcbi.0020041.t002
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Samples
Models of human cancer including xenografts and cell lines
rarely are accompanied by paired normal samples. The utility
of such models may be enhanced if we can ascertain the
patterns of LOH in such models and relate them to those seen
in actual human tumors. To this end, we next asked whether
the HC/LD-HMM could detect regions of common LOH using
11 K SNP array data from 34 prostate cell lines, xenografts,
and metastases where the corresponding normal DNA was
unavailable (RB, unpublished data). We ﬁrst scored each SNP
by averaging the probability of LOH over all 34 samples
(Figure 6, blue curves). The regions with the highest average
probability of LOH correspond to known regions of frequent
LOH, with several known and postulated TSGs lying in or
near the regions with peak LOH scores (Figure 6 and Table
S6). These data suggest that the tumor-only LOH and copy
number inference can be used to detect regions of true LOH
where paired samples are not available.
Discussion
We have developed an HMM-based method to infer the
probability of LOH events from tumor samples without
matched normals. The method utilizes several sources of
information, including intermarker distances, SNP genotyp-
ing and mapping error rates, and haplotype information.
LOH inferences using only tumor samples agree well with
LOH patterns determined by analysis of tumor/normal pairs
in two different array types (10 K and 100 K), three different
tissue types (lung, glioma, and prostate), and in both cell lines
and tumors, in test and in validation datasets. The inferences
are robust to model parameter speciﬁcations. LOH is
resolved to about 3 Mb or 100 SNPs in 100 K array data.
This method makes it feasible to use SNP array technology to
map LOH in tumor samples for which normal DNA is
unavailable. Given that genotyping paired normal samples
constitutes up to half the cost of LOH mapping experiments,
this method also makes it feasible to perform these experi-
ments at a much lower cost per sample, at the expense of
slightly reduced accuracy.
One advantage of a model-based approach over the
existing tumor-only LOH inference methods [3,16] is its
extensibility. The basic HMM was developed using average
heterozygosity rates, but readily extended to incorporate the
SNP-speciﬁc heterozygosity rates and haplotype information
as they became available. In addition, rather than making
deﬁnitive calls the algorithm infers the probability of LOH at
each marker of a sample. This SNP-speciﬁc probability can
then be used in further downstream analyses, such as
identifying regions of shared LOH and sample clustering
[5,24,28]. For example, a high probability of LOH across many
samples can indicate potential TSGs (Figure 6). The HMM
approach can also be used to infer LOH probabilities for
paired normal and tumor samples (see Protocol S1), unifying
the LOH analysis for paired tumor/normal and unpaired
tumor samples.
At higher SNP densities, where the haplotype structure of
the human genome becomes relevant, an approach that
considers the dependence among multiple SNPs in a region
of LD is necessary in addition to the LD-HMM. We used a
haplotype correction that compared regions of inferred
putative LOH to a set of reference normal samples to
reduced false LOH inference. This method works best if the
reference samples have similar haplotypes to the tumor
sample. Use of reference samples from a different ethnic
group tends not to decrease the sensitivity of the method, but
can substantially decrease its speciﬁcity.
False designation of regions of LOH due to allelic
imbalance may lead to paradoxical results, with recurrently
ampliﬁed oncogenes seen as potential TSGs. SNP arrays, by
providing signal intensity along with genotyping data, allow
such regions to be identiﬁed. We can thus integrate these data
to exclude regions of putative LOH with high copy numbers
as likely due to allelic imbalance. At the interpretive level, our
ﬁnding that LOH is often copy-neutral suggests that LOH
and copy loss should be considered independently when
predicting the presence of a TSG, and may best be used in
conjoined analyses.
The ability to identify regions of LOH in tumors without
paired normal DNA allows LOH mapping in the many model
systems lacking paired normal DNA, including cell lines and
xenografts. As such model systems are the platform for
experiments aimed at understanding the biology of human
tumors, it is critical that we understand their genetic
relationship to real human tumors. As an example, among
the prostate cancer samples, LOH at the NKX3.1 locus is
more prevalent among real tumors and xenografts than
among cell lines, LOH at the p53 locus is more prevalent
among xenografts than among real tumors or cell lines, and
LOH at the Rb locus is equally prevalent in all three groups
(Figure 6). Larger sample numbers are required to see
whether these differences are statistically signiﬁcant. Such
studies of the prevalence of regions of LOH across model
systems compared to real tumors may indicate systematic
faults in the ability of model systems to reﬂect in vivo cancer
biology and guide the use and development of appropriate
models based on genetic organization.
SNP array analysis of cancer genomes provides a single
platform for copy number and LOH analysis. As these arrays
move to higher resolution (500K), accounting for the
Figure 5. Correspondence between LOH and Copy Number
For each inferred copy number (x-axis), the proportion of SNP markers (y-
axis) observed in the 10 K dataset of tumor/normal pairs to have
undergone LOH (blue) or retention (red) are shown.
DOI: 10.1371/journal.pcbi.0020041.g005
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these data will be of greater import. The methods described
herein should be readily extensible to both the higher density
arrays and to the increasingly detailed information describing
the haplotype structure of the human genome. The software
package, dChipSNP, is freely available at http://www.dchip.org.
Materials and Methods
Tumor samples and paired normals. We used data from Early
Access 10 K, Mapping 10 K, and 100 K SNP arrays (Affymetrix, Santa
Clara, California, United States) (referred to as 10 K, 11 K and 100 K
arrays, respectively) interrogating, respectively, 10,044, 11,555, and
116,204 SNP loci on all chromosomes except Y, with an average
intermarker distance of 210 kb (11 K array) and 23.6 kb (100 K array)
and average heterozygosity rate of 0.38 (11 K array) and 0.27 (100 K
array) [7–9]. 10 K array data from paired tumor/normal lung and
breast cancer cell lines were previously published [6,15]. 11 K data was
obtained from prostate tumors, cell lines, and xenografts. 100 K data
was obtained from prostate tumors, gliomas, and lung cancer cell
lines, along with paired normal DNA from (respectively) seminal
vesicles, normal brain, and EBV-transformed lymphocytes. Tumor
DNA was isolated from frozen tissue having more than 90% tumor
content. DNA preparation and genotyping were performed accord-
ing to manufacturer’s instructions. Insufﬁcient DNA was available in
the case of one prostate tumor, four EBV-transformed lymphocytes,
and the paired normal for one glioma. In these cases 20 ng of DNA
was subjected to whole-genome ampliﬁcation [29] using the REPLI-g
kit (Qiagen, Valencia, California, United States).
Reference normal samples. The heterozygosity rates for each SNP
and the dependence information between the genotypes of neighbor-
ing SNPs were estimated from sets of normal samples; the haplotype
correction was also performed against separate sets of normal
samples (see Protocol S1). All these reference samples were from
individuals unrelated to the tumor samples under evaluation. The
estimated parameters are stored in genome information ﬁles
available from the dChip website.
Observed LOH calls from paired normal and tumor samples.
dChipSNP [12,28] was used to read CEL and TXT ﬁles containing the
probe intensities and genotype calls (heterozygous AB, homozygous
AA or BB, or missing genotype ‘‘No Call’’) [30]. The paired normal
and tumor data were combined to make LOH calls for each SNP
marker: loss (AB in normal, AA or BB in tumor), retention (AB in
normal and tumor, or No Call in normal and AB in tumor),
noninformative (AA or BB in normal, and the same genotype or No
Call in tumor), or conﬂict (e.g. AA in normal, and AB or BB in tumor).
A HMM was used to infer copy numbers at each SNP position from
the probe level intensity data of the SNP arrays [15]. The positions of
the SNP markers, genes, and cytobands were based on Affymetrix
annotation ﬁles (http://www.affymetrix.com) and the UCSC human
genome assembly (http://genome.ucsc.edu).
Supporting Information
Figure S1. Comparison of the NumHom Method to the HC/LD-HMM
NumHom was applied using window sizes of 33 (with and without
haplotype correction) and 50. Data are displayed as in Figure 3. Red
stars indicate loci where NumHom breaks large regions of LOH into
smaller ones, due to intervening heterozygous markers. Green boxes
outline regions of NumHom-inferred LOH that are then regarded as
retention in the haplotype correction.
Found at DOI: 10.1371/journal.pcbi.0020041.sg001 (99 KB PDF).
Protocol S1. Supplemental Methods and Results
Found at DOI: 10.1371/journal.pcbi.0020041.sd001 (135 KB DOC).
Table S1. The Sensitivity and Speciﬁcity of the Basic HMM, LD-HMM,
HC-HMM, and HC/LD-HMM
The proportion of LOSS and RET markers identiﬁed in paired
tumor/normal data, that were identiﬁed correctly in unpaired tumors
in the 10 K dataset (A), 100 K training dataset (B), and 100 K
validation dataset (C).
Found at DOI: 10.1371/journal.pcbi.0020041.st001 (53 KB DOC).
Table S2. The Sensitivity and Speciﬁcity of the Basic HMM and
Haplotype-Corrected LD-HMM
Ground truth was considered to be the results of a HMM applied to
paired tumor/normal data.
Found at DOI: 10.1371/journal.pcbi.0020041.st002 (32 KB DOC).
Table S3. The Sensitivity and Speciﬁcity of the LD-HMM and HC/LD-
HMM, Using Reference Samples from Alternative Ethnicities
The number and proportion of SNP Markers in the 100 K Validation
Dataset with LOSS or RET in Tumor/Normal Pairs, inferred as LOSS
or RET by the LD-HMM (A) and HC/LD-HMM (B), using reference
samples from alternative ethnicities.
Found at DOI: 10.1371/journal.pcbi.0020041.st003 (35 KB DOC).
Table S4. The Sensitivity and Speciﬁcity of the NumHom Method
Using Different Threshold Window Sizes, Before and After Hap-
lotype Correction
Found at DOI: 10.1371/journal.pcbi.0020041.st004 (28 KB DOC).
Table S5. Sensitivity of the HC/LD-HMM for Regions of LOH
The percentage of LOH regions identiﬁed in 10 K data from tumor/
Figure 6. Inferred LOH in Prostate Cancer Samples Identifies Regions of
LOH Known to Be Frequent in Prostate Cancer
The mean LOH probability across 34 prostate cancer samples is plotted
along the left for all chromosomes. Peak regions of LOH are noted, and
data from Chromosomes 8, 13, and 17 are highlighted on the right.
These data are displayed as in Figure 3. Note that in this view, SNPs are
visualized proportionally to physical distance along the chromosome,
and most SNPs are not projected due to proximity to their neighbors.
The red dotted lines indicate the approximate chromosomal positions of
putative TSGs.
DOI: 10.1371/journal.pcbi.0020041.g006
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Tumor-Only LOH Inference of SNP Datanormal pairs that were also identiﬁed by the HC/LD-HMM applied to
the unpaired tumors, according to the size of the region (A) or
number of SNPs present (B).
Found at DOI: 10.1371/journal.pcbi.0020041.st005 (33 KB DOC).
Table S6. Most Common Regions of LOH in a Set of 34 Prostate
Samples
Found at DOI: 10.1371/journal.pcbi.0020041.st006 (36 KB DOC).
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